Navigation Links
Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
Date:5/29/2012

TI may not use the net proceeds of the Offering as expected as well as risks related to developments in the biopharmaceutical industry, the outcome of preclinicial and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs of developing, producing and selling CTI's drug candidates, that CTI's acquisition of certain assets from S*BIO Pte Ltd. may not be timely completed, if at all, that the projected benefits of such acquisition may not materialize as expected, that CTI may not be able to successfully implement its plans, strategies and objectives related to such acquisition and development of the acquired compounds, the risk that CTI may not be able to sustain its current cost controls, and the risk that CTI may not be able to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling its drug candidates. Further risks and uncertainties include CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to further reduce its operating expenses, that CTI will continue to need to raise capital to fund its operating expenses and may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
www.CellTherapeutics.com/press_room  

Investors Contact:
Ed Bell
T: 206.272.4345

Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
2. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
3. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
4. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
5. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
6. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
7. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
8. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
9. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
10. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORAâ„¢ Oral Calcitonin
11. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... DUBLIN , July 10, 2014 ... the addition of the "International Photonic Integrated ... - Forecasts to 2019" report to their ... The concept of photonic integration traces ... twentieth century. The promise of photonic integration went ...
(Date:7/10/2014)... University of Adelaide research may help in the fight ... can detect tiny quantities of explosives with the use ... the journal Sensors and Actuators B: Chemical , ... can detect explosives in concentrations as low as 6.3 ... of only a few minutes. , "Traditionally explosives detection ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2
... ImQuest Life Sciences today presented important new ... small molecules as antiviral agents at the 13th ... meeting held last week in Washington D.C. ... inhibitors of HBV replication, with two compounds yielding ...
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... and Restated Distribution and License Agreement with its ... the Amended and Restated Distribution and License Agreement, ... Baxter initially entered into a Distribution and License ...
... ST. JOSEPH, Mich., March 31 GeneGo, Inc., the ... Webb, Ph.D., director of the Program of Translational Medicine ... the MetaMiner Oncology Partnership Program. The goal of ... pathway analysis platform built by experts in the ...
Cached Biology Technology:ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C. 2Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 2Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 3Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 4Van Andel Institute Joins the MetaMiner Oncology Partnership Program 2Van Andel Institute Joins the MetaMiner Oncology Partnership Program 3
(Date:7/11/2014)... the Department of Energy,s Oak Ridge National Laboratory ... R&D Magazine in recognition of the year,s top ... tremendous value of our National Labs," said Secretary ... the National Labs continues to help our nation ... and technological innovations necessary to remain globally competitive." ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... protected areas alone are not sufficient for successful biodiversity ... and agricultural land) plays a crucial role in that ... are two land management systems aiming to reconcile the ... retention forestry model is, as the name suggests, based ...
... A new online database combining symptoms, family history and genetic ... a single rogue gene. As described in an article in ... known as PhenoDB, enables any clinician to document cases of ... Hopkins University School of Medicine or the Baylor College of ...
... 2013  Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that it will ... on Wednesday, March 27, 2013 after market close.  In ... conference call with live webcast on Wednesday, March 27, ...
Cached Biology News:New database to speed genetic discoveries 2New database to speed genetic discoveries 3Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results 2Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results 3
Mol wt: average mol wt16,951.27 Da by calculation...
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... set-up Easy to assemble ... tubes, strips or Nunc 96 Well Amplifications ... tray can be fitted directly into the thermal cycler ... thermal cycler formats of major manufacturers Alphanumerically ...
Biology Products: